medigraphic.com
Colegio de Medicina Interna de México.

2017, Number 4

<< Back Next >>

Med Int Mex 2017; 33 (4)

Triglycerides and cardiovascular risk

Carranza-Madrigal J

Language: Spanish
References: 16
Page: 511-514
PDF size: 195.75 Kb.


ABSTRACT

The relationship between triglycerides and cardiovascular risk has led to an information conflict. On the one hand, a strong epidemiological association is suggested, but on the other hand there is a lack of evidence generated by clinical research that its reduction is associated with a decrease in cardiovascular events. In this article we try to explain the possible pathophysiological and methodological reasons for this controversy, we show recent data on the risk analysis of the different types of dyslipidemias found in the clinic, and the probable benefits of treatment with fibrates, as well as practical recommendations of management of the hypertriglyceridaemia-associated dyslipidemias most common in our population.


REFERENCES

  1. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of highdensity lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.

  2. Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.

  3. Castelli WP, Doyle JT, Gordon T, et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation 1977;55:767-72.

  4. The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.

  5. Scott R, OBrien R, Fulcher G, et al. Effects of fenofibrato treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009;32:493-8.

  6. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-7.

  7. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992;85:37-45.

  8. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-91.

  9. Andersson C, Lyass A, Vasan RS, Massaro JM, D’Agostino RB, Robins SJ. Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study. Am Heart J 2014;168:878- 883.e1.

  10. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010;363(7):692-94.

  11. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Published online November 12, 2013 Circulation.

  12. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-1818.

  13. Rohatgi A, Khera A, Berry JD, Givens EG, et al. HDL Cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014;371:2383-93.

  14. Posadas-Romero C, Posadas-Sánchez R, Juárez-Rojas JG, Medina-Urrutia A y col. Alteraciones de las lipoproteínas de alta y baja densidad en pacientes coronarios con C-LDL en meta pero C-HDL y triglicéridos anormales. Arch Cardiol Mex 2008;78:30-39.

  15. Staels B, Dallongeville J, Auwerx J, Schoonjans K, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998;98;2088-2093.

  16. Superko HR, Garrett BC, King III SB, Momary KM, et al. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia. Am J Cardiol 2009




2020     |     www.medigraphic.com